CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 616 enrolled
Drug / intervention
Tranexamic acid (TXA). +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03136445
NCT03136445Phase 3Completed
CompareCT.gov

A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia

NHS Blood and Transplant·interventional·Posted May 2, 2017·Updated Oct 28, 2025

In Brief

A Phase 3 clinical trial evaluating Tranexamic acid (TXA). and Placebo for Hematologic Neoplasms and 2 related conditions. Completed, enrolled 616 participants across 27 sites in 2 countries.

Detailed Summary

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasms, Hemorrhage, Hematopoietic Stem Cell Transplantation
CountriesAustralia, United Kingdom
CollaboratorsNational Health and Medical Research Council, Australia, Monash University

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2, 2017
Enrollment StartJun 1, 2015
Primary CompletionFeb 18, 2022
Study CompletionJun 18, 2022
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.2 years ago

Interventions

Tranexamic acid (TXA).drug

IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.

Placebodrug

IV (saline) or oral placebo tablets